References
Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. (2020). Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Network Open 3: e208857-e208857.
Capel RA, Herring N, Kalla M, Yavari A, Mirams GR, Douglas G, et al. (2015). Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potential. Heart Rhythm 12: 2186-2194.
Chorin E, Dai M, Shulman E, Wadhwani L, Bar-Cohen R, Barbhaiya C, et al. (2020). The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nature Medicine. 10.1038/s41591-020-0888-2
Durcan L, Clarke WA, Magder LS, & Petri M (2015). Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence. J Rheumatol 42:2092-2097.
Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. (1991). Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324: 781-788.
Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents: 105949.
Herring N, Kalla M, & Paterson DJ (2019). The autonomic nervous system and cardiac arrhythmias: current concepts and emerging therapies. Nat Rev Cardiol 16: 707-726.
Hinton D (2020). Food and Drug Administration. FDA Emergency use authorization (EUA) of chloroquine and hydroxychloroquine. . Food and Drug Administration. .
Huang CL (2017). Murine Electrophysiological Models of Cardiac Arrhythmogenesis. Physiol Rev 97: 283-409.
January CT, & Riddle JM (1989). Early afterdepolarizations: mechanism of induction and block. A role for L-type Ca2+ current. Circ Res 64: 977-990.
King JH, Huang CL, & Fraser JA (2013). Determinants of myocardial conduction velocity: implications for arrhythmogenesis. Front Physiol 4: 154.
Lai PC, Ho W, Jain N, & Walters JD (2011). Azithromycin concentrations in blood and gingival crevicular fluid after systemic administration. J Periodontol 82: 1582-1586.
Lane JCE, Weaver J, Kostka K, Duarte-Salles T, Abrahao MTF, Alghoul H, et al. (2020). Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study. medRxiv: 2020.2004.2008.20054551.
Lei M, & Huang CL-H (2019). Cardiac arrhythmogenesis: a tale of two clocks? Cardiovascular Research. 10.1093/cvr/cvz283
Lei M, Wu L, Terrar DA, & Huang CL (2018). Modernized Classification of Cardiac Antiarrhythmic Drugs. Circulation 138: 1879-1896.
Lenzer J (2020). Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence. BMJ 369: m1335.
Magagnoli J, Narendran S, Pereira F, Cummings T, Hardin JW, Sutton SS, et al. (2020). Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv:2020.2004.2016.20065920.
Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. (2020). Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiology. 10.1001/jamacardio.2020.1834
Miller DR, Fiechtner JJ, Carpenter JR, Brown RR, Stroshane RM, & Stecher VJ (1987). Plasma hydroxychloroquine concentrations and efficacy in rheumatoid arthritis. Arthritis Rheum 30: 567-571.
Negami T, Araki M, Okuno Y, & Terada T (2019). Calculation of absolute binding free energies between the hERG channel and structurally diverse drugs. Sci Rep 9: 16586.
NIH (2020). NIH clinical trial of hydroxychloroquine, a potential therapy for COVID-19, begins.
O’Hara T, Virág L, Varró A, & Rudy Y (2011). Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation. PLoS Comput Biol 7: e1002061.
Pharmafield (2020). Novartis sponsors hydroxychloroquine clinical trial in hospitalised COVID-19 patientsed. Morriss E.
Reiz S, & Nath S (1986). Cardiotoxicity of local anaesthetic agents. Br J Anaesth 58: 736-746.
Roden DM, Harrington RA, Poppas A, & Russo AM (2020). Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment. Circulation. 10.1161/circulationaha.120.047521
Saleh M, Gabriels J, Chang D, Kim BS, Mansoor A, Mahmood E, et al. The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection. Circulation: Arrhythmia and Electrophysiology 0. doi:10.1161/CIRCEP.120.008662
Strauss DG, Gintant G, Li Z, Wu W, Blinova K, Vicente J, et al.(2018). Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting. Therapeutic Innovation & Regulatory Science 53: 519-525.